Clinical trials: Pain Cancer
Breast Cancer, Arthralgia
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)
- Conditions
- Breast Cancer, Arthralgia, Osteoporosis
- Trial name
- ART2 (NCT00497458)
- Testing
- Testosterone
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Havah Therapeutics Pty Ltd
Cancer Related Pain (Breakthrough Pain)
A Comparative Study of KW-2246
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in…
- Trial name
- 2246-004 (NCT01326689)
- Testing
- KW-2246
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer, Pain
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00833040
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Talphera, Inc
Cancer Pain
An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain
The purpose of this is study to evaluate improvement of sleep disorder caused by cancer pain after the administration of Hydromorphone Oral Osmotic System (OROS) in Korean participants with cancer.
- Trial name
- NCT00766831
- Testing
- Hydromorphone
- Volunteers
- 190 people
- Sponsor
- Janssen Korea, Ltd., Korea
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901328
- Testing
- CB-5945
- Volunteers
- 49 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer, Breakthrough Pain
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the management of breakthrough pain (BTP) compared to placebo treatment in children with cancer and non-cancer pain who are receiving…
- Trial name
- NCT00236041
- Testing
- ACTIQ®
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- Cephalon
Osteoarthritis, Knee
Investigating the Effect of Deep Sea Krill Oil Supplementation in Osteoarthritis of the Knee
To evaluate the effectiveness of 4 g Swisse High Strength Deep Sea Krill Oil (Superba BOOST) daily on pain reduction in adults with mild to moderate osteoarthritis of the knee compared to placebo over a 6 month period.
- Trial name
- NCT03483090
- Testing
- Swisse High Strength Deep Sea Krill Oil
- Where
- 4 sites in Australia
- Volunteers
- 235 people
- Sponsor
- Swisse Wellness Pty Ltd
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer
This study will evaluate renal function in participants with metastatic bone disease due to breast cancer receiving intravenous (IV) infusions of ibandronate (Bondronat) 6 milligrams (mg), over either 15 minutes or 60 minutes…
- Trial name
- NCT02716792
- Testing
- Ibandronate
- Where
- 30 sites in France
- Volunteers
- 334 people
- Sponsor
- Hoffmann-La Roche
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
Cancer, Chronic Pain
Tapentadol in Chronic Malignant Tumour Related Pain
The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain.
- Conditions
- Cancer, Chronic Pain, Pain
- Trial name
- NCT01264887
- Testing
- Tapentadol Prolonged Release
- Where
- 12 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 31 people
- Sponsor
- Grünenthal GmbH
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Improving Pain Management in Patients With Nonhematologic Cancer
RATIONALE: A pain assessment and management system for people with cancer may help doctors accurately assess and plan more effective pain treatment for patients who have cancer.
- Trial name
- NCT00036829
- Testing
- pain therapy
- Where
- United States
- Sponsor
- Inflexxion, Inc.
Knee Osteoarthritis
Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial
The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device in patients with stage I and stage II knee osteoarthritis.
- Trial name
- NCT02083861
- Testing
- Sam Ultrasonic Diathermy Device
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- ZetrOZ, Inc.
Cancer Pain
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorohone Hydrochloride (HCl) compared with morphine sustain release (SR) in participants with chronic (lasting a…
- Trial name
- NCT00803283
- Testing
- Hydromprphone Hydrochloride (HCl) OROS, Morphine Sustain Release (SR)
- Volunteers
- 2 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Pain
Analgesic Treatment for Cancer Pain in South East Asia
This study is planned to investigate the pain control status in cancer patients in 6 South East Asian countries through evaluation of prescription pattern of analgesics, satisfaction of pain control, quality of life and…
- Trial name
- ACE (NCT02664987)
- Testing
- Patients receiving cancer pain treatment
- Volunteers
- 462 people
- Sponsor
- Mundipharma Pte Ltd.
Pain, Neoplasms
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release…
- Conditions
- Pain, Neoplasms, Chronic Pain
- Trial name
- CORAL (NCT01964378)
- Testing
- Cebranopadol, Morphine Prolonged Release
- Where
- 42 sites in Austria, Belgium and 12 more
- Volunteers
- 200 people
- Sponsor
- Tris Pharma, Inc.
Pain, Cancer
Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method
This study evaluates colonic analgesia by comparing two novel formulations, GIC-1001 and GIC-1002 with placebo using a barostat distender.
- Conditions
- Pain, Cancer, Colonic Disease
- Trial name
- NCT02276768
- Testing
- GIC-1001 375 mg TID, GIC-1001 500 mg TID, GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- gicare Pharma Inc.
Pain, Analgesics, Opioid
Safety and Tolerability of Long-Term Administration of Hydromorphone HCI CR (Controlled Release)
The purpose of study was to characterize the safety and tolerability of long-term repeated dosing of OROS hydromorphone controlled release tablets (8,16,32, and 64 mg) in patients with chronic cancer pain or chronic non-malignant…
- Trial name
- NCT00410748
- Testing
- OROS hydromorphone HCI CR
- Volunteers
- 388 people
- Sponsor
- Alza Corporation, DE, USA
Pain, Analgesics, Opioid
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
The purpose of this study was to demonstrate the clinical equivalence of hydromorphone and morphine (immediate-release [IR] and sustained-release [SR] formulations) using the "worst pain in the past 24 hours" item of the Brief…
- Trial name
- NCT00410540
- Testing
- OROS hydromorphone HCL ; Morphine sulfate
- Volunteers
- 202 people
- Sponsor
- Alza Corporation, DE, USA
Pain, Chronic
Ziconotide for Non-cancer Pain by Intrathecal Administration
Although ziconotide's marketing authorization does not restrict its use to a given type of pain, the drug has been used mainly in cancer patients.
- Trial name
- NCT06541184
- Testing
- Ziconotide [Prialt]
- Where
- 14 sites in France
- Volunteers
- 85 people
- Sponsor
- ESTEVE Pharmaceuticals SAS
Pain, Cancer
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293020
- Testing
- BEMA Fentanyl
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BioDelivery Sciences International